3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Hematologic Neoplasms
10
Multiple Myeloma
8
Lymphoma
5
Leukemia, Myeloid, Acute
5
Neoplasms
4
Glioma
3
Thyroid Carcinoma, Anaplastic
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neurofibromatosis 1
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Melanoma
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Interventions
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
trametinib
1
pertuzumab
1
dabrafenib
1
atezolizumab
1
abexinostat
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
trametinib
×
Other hematologic neoplasm
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled